Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.
Stocks · News reference
Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders
-SEC Filing